To include your compound in the COVID-19 Resource Center, submit it here.

Lilly revamping presence in China

As part of an evolving research strategy in China, Eli Lilly and Co. (NYSE:LLY) will close its R&D center in Shanghai and instead seek to expand partnerships with local biotechs and academics. Spokesperson Lauren

Read the full 348 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers